Table 4. Comparing the relative efficacy of interventions with respect to three-year survival status using pairwise and network meta-analysis.
| TACE | TACE +EBRT | TACE +HIFU | TACE +PEI | TACE +RFA | TACE +RT | TACE +SOR | TARE -90Y | DEB -TACE | PAI | PEI | RFA | RT | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TACE | 0.69 (0.59, 0.80) | 0.41 (0.35, 0.48) | 0.50 (0.43, 0.56) | 0.56 (0.46, 0.65) | 0.54 (0.48, 0.60) | 0.64 (0.56, 0.72) | 0.84 (0.77, 0.90) | 0.50 (0.44, 0.56) | - | - | 0.80 (0.69, 0.91) | 0.44 (0.34, 0.54) | |
| TACE+EBRT | 0.69 (0.32, 1.50) | - | - | - | - | - | - | - | - | - | - | - | |
| TACE+HIFU | 0.41 (0.19, 0.90) | 0.59 (0.20, 1.79) | - | - | - | - | - | - | - | - | - | - | |
| TACE+PEI | 0.77 (0.53, 1.13) | 1.12 (0.47, 2.67) | 1.89 (0.79, 4.50) | - | - | - | - | - | - | 1.39 (0.82, 4.55) | - | - | |
| TACE+RFA | 0.52 (0.35, 0.78) | 0.75 (0.31, 1.81) | 1.26 (0.52, 3.04) | 0.67 (0.39, 1.13) | - | - | - | - | - | - | 1.76 (1.56, 2.00) | - | |
| TACE+RT | 0.45 (0.29, 0.69) | 0.65 (0.27, 1.58) | 1.09 (0.45, 2.66) | 0.58 (0.33, 1.02) | 0.87 (0.48, 1.56) | - | - | - | - | - | - | 5.56 (4.44, 7.41) | |
| TACE+SOR | 0.71 (0.45, 1.13) | 1.04 (0.42, 2.56) | 1.74 (0.71, 4.31) | 0.92 (0.51, 1.67) | 1.38 (0.75, 2.54) | 1.60 (0.85, 2.98) | - | - | - | - | - | - | |
| TARE-90Y | 0.84 (0.57, 1.25) | 1.22 (0.51, 2.93) | 2.06 (0.86, 4.93) | 1.09 (0.63, 1.88) | 1.63 (0.93, 2.86) | 1.89 (1.06, 3.36) | 1.18 (0.65, 2.16) | - | - | - | - | - | |
| DEB-TACE | 0.64 (0.46, 0.89) | 0.93 (0.40, 2.16) | 1.56 (0.67, 3.64) | 0.83 (0.50, 1.36) | 1.23 (0.73, 2.08) | 1.43 (0.83, 2.44) | 0.89 (0.51, 1.57) | 0.76 (0.45, 1.26) | - | - | - | - | |
| PAI | 1.25 (0.49, 3.20) | 1.81 (0.53, 6.14) | 3.05 (0.90, 10.35) | 1.62 (0.61, 4.30) | 2.42 (0.96, 6.07) | 2.79 (1.00, 7.83) | 1.75 (0.62, 4.97) | 1.48 (0.54, 4.09) | 1.96 (0.72, 5.29) | 1.14 (0.93, 1.45) | - | - | |
| PEI | 1.42 (0.86, 2.34) | 2.06 (0.82, 5.20) | 3.47 (1.37, 8.76) | 1.84 (1.04, 3.24) | 2.75 (1.73, 4.37) | 3.17 (1.65, 6.11) | 1.99 (1.01, 3.91) | 1.68 (0.89, 3.17) | 2.22 (1.22, 4.04) | 1.14 (0.51, 2.52) | 0.48 (0.41, 0.55) | - | |
| RFA | 0.81 (0.55, 1.21) | 1.18 (0.49, 2.83) | 1.99 (0.83, 4.77) | 1.05 (0.63, 1.75) | 1.57 (1.15, 2.15) | 1.82 (1.02, 3.25) | 1.14 (0.62, 2.09) | 0.96 (0.55, 1.68) | 1.27 (0.76, 2.13) | 0.65 (0.27, 1.56) | 0.57 (0.40, 0.82) | - | |
| RT | 1.04 (0.57, 1.90) | 1.50 (0.56, 4.03) | 2.53 (0.94, 6.79) | 1.34 (0.66, 2.73) | 2.00 (0.97, 4.15) | 2.32 (1.26, 4.24) | 1.45 (0.68, 3.10) | 1.23 (0.60, 2.52) | 1.62 (0.82, 3.23) | 0.83 (0.27, 2.53) | 0.73 (0.33, 1.60) | 1.27 (0.62, 2.62) |
1. The cells in blue are results of pair-wise meta-analysis and the column treatment is compared with the row treatment. The results are presented by hazard ratio (HR) and 95% credible interval (CrI). The cells in red are results of network meta-analysis and the row treatment is compared with the column treatment. The results are presented by hazard ratio (HR) and 95% credible interval (CrI).
2. TACE: transcatheter arterial chemoembolization; EBRT: external-beam radiation therapy; HIFU: high intensity focused ultrasound; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation; RT: radiotherapy; SOR: sorafenib; TARE-90Y: yttrium-90 radioembolization; DEB-TACE: drug-eluting beads-transcatheter arterial chemoembolization; PAI: percutaneous acetic acid injection.